Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Medical School, Boston, MA, USA; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Clinical and Epidemiological Research, Hospital Universitario at University of Sao Paulo, Sao Paulo, SP, Brazil.
Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Medical School, Boston, MA, USA.
J Clin Lipidol. 2017 Sep-Oct;11(5):1257-1267.e2. doi: 10.1016/j.jacl.2017.06.008. Epub 2017 Jun 21.
Type II diabetes (T2D) is preceded by prolonged insulin resistance and relative insulin deficiency incompletely captured by glucose metabolism parameters, high-density lipoprotein (HDL) cholesterol and triglycerides.
Whether lipoprotein insulin resistance (LPIR) score, a metabolomic marker, is associated with incident diabetes and improves risk reclassification over traditional markers on extended follow-up.
Among 25,925 nondiabetic women aged 45 years or older, LPIR was measured by nuclear magnetic resonance spectroscopy as a weighted score of very low density lipoprotein, low-density lipoprotein, and HDL particle sizes, and their subsets concentrations. We run adjusted cox regression models for LPIR with incident T2D (20.4 years median follow-up).
Adjusting for demographics, body mass index, life style factors, blood pressure, and T2D family history, the LPIR hazard ratio for T2D (hazard ratio [HR] per standard deviation, 95% confidence interval) was 1.95 (1.85, 2.06). Further adjusting for HbA1c, C-reactive protein, triglycerides, HDL and low-density lipoprotein cholesterol, LPIR HR was attenuated to 1.41 (1.31, 1.53) and had the strongest association with T2D after HbA1C in mutually adjusted models. The association persisted even in those with optimal clinical profiles, adjusted HR per standard deviation 1.91 (1.17, 3.13). In participants deemed at intermediate T2D risk by the Framingham Offspring T2D score, LPIR led to a net reclassification of 0.145 (0.117, 0.175).
In middle-aged or older healthy women followed prospectively for over 20 years, LPIR was robustly associated with incident T2D, including among those with an optimal clinical metabolic profile. LPIR improved T2D risk classification and may guide early and targeted prevention strategies.
2 型糖尿病(T2D)之前存在长期的胰岛素抵抗和相对胰岛素缺乏,这些情况不能仅通过葡萄糖代谢参数、高密度脂蛋白(HDL)胆固醇和甘油三酯来完全捕捉。
脂蛋白胰岛素抵抗(LPIR)评分是一种代谢组学标志物,它是否与糖尿病的发生有关,并且在延长的随访中是否优于传统标志物来改善风险分类。
在 25925 名年龄在 45 岁或以上的非糖尿病女性中,通过核磁共振光谱法测量 LPIR,作为极低密度脂蛋白、低密度脂蛋白和 HDL 颗粒大小及其亚群浓度的加权评分。我们使用调整后的 Cox 回归模型来分析 LPIR 与 T2D (中位随访时间 20.4 年)的关系。
在调整了人口统计学、体重指数、生活方式因素、血压和 T2D 家族史后,LPIR 发生 T2D 的风险比(风险比[HR]每标准差,95%置信区间)为 1.95(1.85,2.06)。进一步调整 HbA1c、C 反应蛋白、甘油三酯、HDL 和低密度脂蛋白胆固醇后,LPIR HR 减弱至 1.41(1.31,1.53),并且在相互调整模型中与 T2D 的相关性最强。即使在那些具有最佳临床特征的人群中,每标准差的调整 HR 为 1.91(1.17,3.13),这种关联仍然存在。在根据弗雷明汉后代 T2D 评分被认为处于 T2D 中等风险的参与者中,LPIR 导致净再分类为 0.145(0.117,0.175)。
在前瞻性随访超过 20 年的中年或老年健康女性中,LPIR 与 T2D 的发生密切相关,包括在那些具有最佳临床代谢特征的人群中。LPIR 改善了 T2D 风险分类,可能指导早期和有针对性的预防策略。